Genomic Characterization of Concurrent Alterations in Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Mutations.
ALK
BRAF
EGFR
ERBB2
KRAS
MET
RET
co-mutation
next generation sequencing
predictive biomarker
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
30 Apr 2021
30 Apr 2021
Historique:
received:
16
04
2021
revised:
27
04
2021
accepted:
27
04
2021
entrez:
5
5
2021
pubmed:
6
5
2021
medline:
6
5
2021
Statut:
epublish
Résumé
An increasing number of driver genomic alterations with potential targeted treatments have been identified in non-small cell lung cancer (NSCLC). Much less is known about the incidence and different distribution of concurrent alterations, as identified by comprehensive genomic profiling in oncogene-addicted NSCLCs. Genomic data from advanced NSCLC consecutively analyzed using a broad next-generation sequencing panel were retrospectively collected. Tumors harboring at least one main actionable gene alteration were categorized according to the presence/absence of concurrent genomic aberrations, to evaluate different patterns among the main oncogene-addicted NSCLCs. Three-hundred-nine actionable gene alterations were identified in 284 advanced NSCLC patients during the study period. Twenty-five tumor samples (8%) displayed concurrent alterations in actionable genes. Co-occurrences involving any pathogenic variant or copy number variation (CNV) were identified in 82.8% of cases. Overall, statistically significant differences in the number of concurrent alterations, and the distribution of
Identifiants
pubmed: 33946519
pii: cancers13092172
doi: 10.3390/cancers13092172
pmc: PMC8124171
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Cancer Discov. 2018 Jul;8(7):822-835
pubmed: 29773717
N Engl J Med. 2017 Jun 1;376(22):2109-2121
pubmed: 28445112
Clin Cancer Res. 2018 Mar 1;24(5):1038-1047
pubmed: 29217530
J Thorac Oncol. 2021 May;16(5):764-773
pubmed: 33333327
Clin Cancer Res. 2018 Jul 1;24(13):3108-3118
pubmed: 29530932
Lung Cancer. 2021 Apr;154:151-160
pubmed: 33684660
Cancer Treat Rev. 2021 May;96:102179
pubmed: 33798954
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Cancer Discov. 2021 Apr;11(4):810-814
pubmed: 33811117
Cell. 2012 Sep 14;150(6):1107-20
pubmed: 22980975
J Clin Pathol. 2018 Sep;71(9):767-773
pubmed: 29535211
J Thorac Oncol. 2019 Feb;14(2):193-202
pubmed: 30391576
Cell. 2017 Feb 9;168(4):613-628
pubmed: 28187284
ESMO Open. 2020 Oct;5(5):e000919
pubmed: 33067323
Signal Transduct Target Ther. 2019 Dec 17;4:61
pubmed: 31871778
Nat Med. 2017 Jun;23(6):703-713
pubmed: 28481359
Lung Cancer. 2017 Sep;111:23-29
pubmed: 28838393
JAMA. 2014 May 21;311(19):1998-2006
pubmed: 24846037
Cancer Treat Rev. 2020 Sep;89:102085
pubmed: 32771858
Br J Cancer. 2020 Jul;123(1):81-91
pubmed: 32376889
J Clin Oncol. 2017 Sep 10;35(26):3065-3074
pubmed: 28498782
Stem Cells. 2018 May;36(5):633-640
pubmed: 29352734
Cell. 2019 Jun 13;177(7):1842-1857.e21
pubmed: 31155235
Trends Cancer. 2016 Mar;2(3):144-158
pubmed: 28435907
Cancer Discov. 2015 Aug;5(8):860-77
pubmed: 26069186
Cancer Discov. 2015 Aug;5(8):850-9
pubmed: 25971938
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Transl Lung Cancer Res. 2021 Jan;10(1):202-220
pubmed: 33569305
Transl Lung Cancer Res. 2020 Oct;9(5):1810-1821
pubmed: 33209603
N Engl J Med. 2004 May 20;350(21):2129-39
pubmed: 15118073
Nat Genet. 2017 Dec;49(12):1693-1704
pubmed: 29106415
Lung Cancer. 2017 Apr;106:17-21
pubmed: 28285689
Breast Cancer Res. 2020 Oct 15;22(1):107
pubmed: 33059724